HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.
about
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyAntidrug Antibodies: B Cell Immunity Against TherapyBiomarkers of treatment response in multiple sclerosisHuman leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosisOccurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort AnalysisT cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donorsHLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Immunogenicity to biologics: mechanisms, prediction and reduction.In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteersClinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.Risk conferring genes in multiple sclerosis.Treatment of multiple sclerosis: current concepts and future perspectives.Overcoming immunogenicity associated with the use of biopharmaceuticals.Pharmacogenomics in neurology: current state and future steps.Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers.Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.Comparative immunogenicity assessment: a critical consideration for biosimilar development.Body fluid biomarkers for multiple sclerosis--the long road to clinical application.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.[Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a.Modulating the immune system through nanotechnology.Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases.Genetic correlations of brain lesion distribution in multiple sclerosis: an exploratory study.Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis.Evidence-based practice in psychiatric and mental health nursing: qualitative meta-synthesis.Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy.Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients.Identification of HLA-DRB1 association to adalimumab immunogenicity.HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study
P2860
Q26745516-6817E4BA-E095-4726-A1F3-C643CBFCB8EFQ28082303-9B5EC785-601B-4A01-AEB4-D714550A4FD7Q28305094-097DAE6A-EBD8-434A-92AD-2B0C55DEBA73Q28540630-48D394EF-A713-419C-8729-8C652BBA67BBQ28553133-511A534F-E1A4-4A1A-A8E7-197A236F1894Q28704590-1AF01355-5C66-4779-9B1B-C5969E5499E8Q30371340-96B9DC27-4B0B-440A-9AED-44295D1D12B3Q34296526-15332F99-2BCA-4D80-A473-D4C32DC0E506Q34316771-7BBF48AF-941C-4A8D-9AC2-4B45A2EA8129Q36272813-5C60BC72-1FD8-46EA-882C-865EC852067CQ37857943-828C7058-DE8D-4DE0-9106-46B1359CAC53Q37884434-D3C47A5C-EF15-40E0-9977-6AC0F3666060Q37960542-417F516C-ACB0-48D5-AD03-02A3F072C036Q37967607-7DF60CB3-72DF-4101-A303-CB7E8148FDAEQ37990779-EDE583E1-57B1-43CD-9345-9C9F24EA552AQ38151885-16BA5710-603B-48EB-9ED2-D8E915B7C938Q38174450-A2E99A0B-74C9-405E-BAF9-AC401B2FB492Q38361902-C35AF4F5-4A0A-41AA-8DE9-490EDC52C487Q38590773-2EE2EB70-4575-4631-B7EF-1E02F39E678CQ38960854-DF0C4724-4476-43D3-B63E-83429DE84E36Q38984981-E99F8E25-3EDF-46D3-9CB2-9D4B1D9D6A5CQ40957502-60B99F3A-67C9-4D29-873E-F8E06667D7E1Q45155454-88FFE55E-FBF2-4051-A529-5734C41893D5Q45761961-C171F209-D7A5-4383-8CE1-36DC22FE95CDQ45801403-ECBE2999-ADA4-49A2-A7AE-2FD9514DCE36Q47835401-E88AA718-731C-4B05-9FDF-202E88C16EF5Q48630939-A51E5CF8-8D7E-41EF-BD5E-75257AC3B27BQ50073706-EA234BB0-978F-40FA-B3E1-DCDDB85CAA50Q51550108-E4C4DBE1-EEA3-476B-B9C1-6F2F2DFF8740Q51558970-746BE3F5-03E4-44E5-9C12-D88BF82B8BB4Q51878455-652D72C0-708D-437E-BC81-F938AD0C7325Q53080382-2220F4DD-2038-4C06-A8F7-A114B912DDD7Q54311380-B08989F8-6C90-4B1C-8145-7C79D7B8F8DFQ54665285-A6F2F344-4CC3-4C08-BEBA-FD46C3200BF6Q55284744-D5859DC5-C1CA-45B2-B878-4AA07F594044Q57083577-0055EA26-48A3-4B05-B533-C3C78C9C2676
P2860
HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
HLA-DRB1*0401 and HLA-DRB1*040 ...... therapy in multiple sclerosis.
@ast
HLA-DRB1*0401 and HLA-DRB1*040 ...... therapy in multiple sclerosis.
@en
type
label
HLA-DRB1*0401 and HLA-DRB1*040 ...... therapy in multiple sclerosis.
@ast
HLA-DRB1*0401 and HLA-DRB1*040 ...... therapy in multiple sclerosis.
@en
prefLabel
HLA-DRB1*0401 and HLA-DRB1*040 ...... therapy in multiple sclerosis.
@ast
HLA-DRB1*0401 and HLA-DRB1*040 ...... therapy in multiple sclerosis.
@en
P2093
P2860
P50
P1476
HLA-DRB1*0401 and HLA-DRB1*040 ...... therapy in multiple sclerosis.
@en
P2093
Achim Berthele
Bernhard Hemmer
Florian Deisenhammer
Klaus Lehmann-Horn
Ralf Wassmuth
Sabine Cepok
Steve Hoffmann
Verena Grummel
P2860
P304
P356
10.1016/J.AJHG.2008.07.006
P407
P577
2008-07-24T00:00:00Z